4-hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: A toxic combination illuminated by redox proteomics studies

Antioxidants and Redox Signaling

Volumn 17, Issue 11, 2012, Pages 1590-1609

  Perluigi, Marzia ^a   Coccia, Raffaella ^a   Allan Butterfield, D ^b,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROPEROXYOCTADECADIENOIC ACID; 4 HYDROXYNONENAL; ACID; ACONITATE HYDRATASE; ACROLEIN; ALPHA ENOLASE; AMYLOID BETA PROTEIN[1-40]; ARACHIDONIC ACID; BIOLOGICAL MARKER; CATALASE; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; COPPER ZINC SUPEROXIDE DISMUTASE; FREE RADICAL; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HEAT SHOCK PROTEIN 70; HEME OXYGENASE 1; IRON SUPEROXIDE DISMUTASE; ISOPROSTANE DERIVATIVE; LACTATE DEHYDROGENASE; MALATE DEHYDROGENASE; MALONALDEHYDE; MANGANESE SUPEROXIDE DISMUTASE; NEUROPROSTANE; PEROXIREDOXIN; PEROXY RADICAL; PHOSPHATIDYLCHOLINE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SCAVENGER; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; ARACHIDONIC ACID METABOLISM; CELL COMMUNICATION; CEREBROVASCULAR ACCIDENT; CYTOSKELETON; DEGENERATIVE DISEASE; DIAGNOSTIC VALUE; DISEASE COURSE; DOWN SYNDROME; ENERGY METABOLISM; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; LABORATORY TEST; LIPID PEROXIDATION; MICHAEL ADDITION; MILD COGNITIVE IMPAIRMENT; MITOCHONDRION; MULTIPLE SCLEROSIS; NERVE CELL; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN SYNTHESIS; PROTEOMICS; REVIEW; SENILE PLAQUE;

ALDEHYDES; ANTIOXIDANTS; FATTY ACIDS, UNSATURATED; HUMANS; LIPID PEROXIDATION; MALONDIALDEHYDE; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS;

EID: 84866848255     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.4406     Document Type: Review

References (217)

1. Abe K, Pan LH, Watanabe M, Kato T, and Itoyama Y. Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neurosci Lett 199: 152-154, 1995.
2. Adibhatla RM and Hatcher JF. Phospholipase A(2), reactive oxygen species, and lipid peroxidation in CNS pathologies. BMB Rep 41: 560-567, 2008.
3. Aldini G, Vistoli G, Regazzoni L, Gamberoni L, Facino RM, Yamaguchi S, Uchida K, and Carini M. Albumin is the main nucleophilic target of human plasma: a protective role against pro-atherogenic electrophilic reactive carbonyl species? Chem Res Toxicol 21: 824-835, 2008. (Pubitemid 351644560)
4. Aluise CD, Robinson RA, Beckett TL, Murphy MP, Cai J, Pierce WM, Markesbery WR, and Butterfield DA. Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics. Neurobiol Dis 39: 221-228, 2010.
5. Aluise CD, Robinson RA, Cai J, Pierce WM, Markesbery WR, and Butterfield DA. Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: insights into memory loss in MCI. J Alzheimers Dis 23: 257-269, 2011.
6. Anantharaman M, Tangpong J, Keller JN, Murphy MP, Markesbery WR, Kiningham KK, and St Clair DK. Beta-amyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer's disease. Am J Pathol 168: 1608-1618, 2006.
7. Andersen PM. Genetic factors in the early diagnosis of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 1 Suppl 1: S31-42, 2000.
8. Andrus PK, Fleck TJ, Gurney ME, and Hall ED. Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 71: 2041-2048, 1998. (Pubitemid 28491560)
9. Anzai K, Ogawa K, Goto Y, Senzaki Y, Ozawa T, and Yamamoto H. Oxidation-dependent changes in the stability and permeability of lipid bilayers. Antioxid Redox Signal 1: 339-347, 1999. (Pubitemid 129622804)
10. Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 118: 167-179, 2009.
11. Arimura N, Inagaki N, Chihara K, Menager C, Nakamura N, Amano M, Iwamatsu A, Goshima Y, and Kaibuchi K. Phosphorylation of collapsin response mediator protein-2 by Rho-kinase. Evidence for two separate signaling pathways for growth cone collapse. J Biol Chem 275: 23973-23980, 2000. (Pubitemid 30624686)
12. Atamna H and Frey WH 2nd. Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. Mitochondrion 7: 297-310, 2007. (Pubitemid 47300175)
13. Bader Lange ML, Cenini G, Piroddi M, Abdul HM, Sultana R, Galli F, Memo M, and Butterfield DA. Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease. Neurobiol Dis 29: 456-464, 2008.
14. Bader Lange ML, St Clair D, Markesbery WR, Studzinski CM, Murphy MP, and Butterfield DA. Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease. Neurobiol Dis 38: 104-115, 2010.
15. Balcz B, Kirchner L, Cairns N, Fountoulakis M, and Lubec G. Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J Neural Transm Suppl (61): 193-201, 2001. (Pubitemid 38085082)
16. Ball MJ and Nuttall K. Neurofibrillary tangles, granulovacuolar degeneration, and neuron loss in Down syndrome: quantitative comparison with Alzheimer dementia. Ann Neurol 7: 462-465, 1980. (Pubitemid 10073126)
17. Barber SC and Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 48: 629-641, 2010.
18. Battaini F, Pascale A, Lucchi L, Pasinetti GM, and Govoni S. Protein kinase C anchoring deficit in postmortem brains of Alzheimer's disease patients. Exp Neurol 159: 559-564, 1999. (Pubitemid 29485243)
19. Beal MF. Neurochemistry and toxin models in Huntington's disease. Curr Opin Neurol 7: 542-547, 1994.
20. Beckman JS, Chen J, Crow JP, and Ye YZ. Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration. Prog Brain Res 103: 371-380, 1994.
21. Behl C. Vitamin E and other antioxidants in neuroprotection. Int J Vitam Nutr Res 69: 213-219, 1999. (Pubitemid 29266983)
22. Bigl M, Bruckner MK, Arendt T, Bigl V, and Eschrich K. Activities of key glycolytic enzymes in the brains of patients with Alzheimer's disease. J Neural Transm 106: 499-511, 1999. (Pubitemid 29273888)
23. Bonini NM and Giasson BI. Snaring the function of alphasynuclein. Cell 123: 359-361, 2005.
24. Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P, Goolsby H, Fontaine BA, Lemay N, McKenna-Yasek D, Frosch MP, Agar JN, Julien JP, Brady ST, and Brown RH Jr. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 13: 1396-1403, 2010.
25. Boyd-Kimball D, Castegna A, Sultana R, Poon HF, Petroze R, Lynn BC, Klein JB, and Butterfield DA. Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res 1044: 206-215, 2005. (Pubitemid 40693453)
26. Browne SE and Beal MF. Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal 8: 2061-2073, 2006. (Pubitemid 46489631)
27. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, and Beal MF. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41: 646-653, 1997. (Pubitemid 27212659)
28. Browne SE, Ferrante RJ, and Beal MF. Oxidative stress in Huntington's disease. Brain Pathol 9: 147-163, 1999. (Pubitemid 29056525)
29. Bruening W, Roy J, Giasson B, Figlewicz DA, Mushynski WE, and Durham HD. Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis. J Neurochem 72: 693-699, 1999. (Pubitemid 29055232)
30. Bubber P, Haroutunian V, Fisch G, Blass JP, and Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57: 695-703, 2005. (Pubitemid 40628858)
31. Busciglio J and Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378: 776-779, 1995. (Pubitemid 26004408)
32. Butterfield DA, Bader Lange ML, and Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim Biophys Acta 1801: 924-929, 2010.
33. Butterfield DA and Castegna A. Proteomics for the identification of specifically oxidized proteins in brain: technology and application to the study of neurodegenerative disorders. Amino Acids 25: 419-425, 2003. (Pubitemid 38041276)
34. Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P, Fombonne J, Gorostiza O, Zhang J, Sultana R, and Bredesen DE. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic Biol Med 48: 136-144, 2010.
35. Butterfield DA, Hensley K, Cole P, Subramaniam R, Aksenov M, Aksenova M, Bummer PM, Haley BE, and Carney JM. Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer's disease. J Neurochem 68: 2451-2457, 1997. (Pubitemid 27218166)
36. Butterfield DA and Lange ML. Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J Neurochem 111: 915-933, 2009.
37. Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WM, Klein JB, and Markesbery WR. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis 22: 223-232, 2006.
38. Butterfield DA, Reed T, Perluigi M, De Marco C, Coccia R, Cini C, and Sultana R. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett 397: 170-173, 2006.
39. Butterfield DA and Stadtman ER. Protein Oxidation processes in aging brain. Adv Cell Aging Gerontol 2: 161-191, 1997.
40. Cadenas E, Muller A, Brigelius R, Esterbauer H, and Sies H. Effects of 4-hydroxynonenal on isolated hepatocytes. Studies on chemiluminescence response, alkane production and glutathione status. Biochem J 214: 479-487, 1983. (Pubitemid 13035530)
41. Calabrese V, Scapagnini G, Ravagna A, Colombrita C, Spadaro F, Butterfield DA, and Giuffrida Stella AM. Increased expression of heat shock proteins in rat brain during aging: relationship with mitochondrial function and glutathione redox state. Mech Ageing Dev 125: 325-335, 2004. (Pubitemid 38438512)
42. Campos C, Guzman R, Lopez-Fernandez E, and Casado A. Evaluation of urinary biomarkers of oxidative/nitrosative stress in adolescents and adults with Down syndrome. Biochim Biophys Acta 1812: 760-768, 2011.
43. Capone GT. Down syndrome: advances in molecular biology and the neurosciences. J Dev Behav Pediatr 22: 40-59, 2001. (Pubitemid 33040477)
44. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, and Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxyterminal hydrolase L-1. Free Radic BiolMed 33: 562-571, 2002. (Pubitemid 34874977)
45. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, and Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinaserelated protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82: 1524-1532, 2002.
46. Castegna A, Lauderback CM, Mohmmad-Abdul H, and Butterfield DA. Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer's disease. Brain Res 1004: 193-197, 2004. (Pubitemid 38368075)
47. Caudle WM, Pan S, Shi M, Quinn T, Hoekstra J, Beyer RP, Montine TJ, and Zhang J. Proteomic identification of pro-teins in the human brain: Towards a more comprehensive understanding of neurodegenerative disease. Proteomics Clin Appl 2: 1484-1497, 2008.
48. Chen ZH, Saito Y, Yoshida Y, Sekine A, Noguchi N, and Niki E. 4-Hydroxynonenal induces adaptive response and enhances PC12 cell tolerance primarily through induction of thioredoxin reductase 1 via activation of Nrf2. J Biol Chem 280: 41921-41927, 2005. (Pubitemid 43023161)
49. Cleveland DW and Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2: 806-819, 2001. (Pubitemid 33674062)
50. Dalle Donne I, Scaloni A, and Butterfield DA. Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Diseases. Hoboken, NJ: John Wiley and Sons, 2006.
51. Davies P. Challenging the cholinergic hypothesis in Alzheimer disease. JAMA 281: 1433-1434, 1999. (Pubitemid 29190223)
52. Davis BM, Mohs RC, Greenwald BS, Mathe AA, Johns CA, Horvath TB, and Davis KL. Clinical studies of the cholinergic deficit in Alzheimer's disease. I. Neurochemical and neuroendocrine studies. J Am Geriatr Soc 33: 741-748, 1985. (Pubitemid 16183969)
53. Demicheli V, Quijano C, Alvarez B, and Radi R. Inactivation and nitration of human superoxide dismutase (SOD) by fluxes of nitric oxide and superoxide. Free Radic Biol Med 42: 1359-1368, 2007. (Pubitemid 46467271)
54. Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, Rusinek H, Pelton GH, Honig LS, Mayeux R, Stern Y, Tabert MH, and de Leon MJ. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 68: 828-836, 2007. (Pubitemid 46568534)
55. Dexter D, Carter C, Agid F, Agid Y, Lees AJ, Jenner P, and Marsden CD. Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet 2: 639-640, 1986. (Pubitemid 16055627)
56. Dhitavat S, Rivera ER, Rogers E, and Shea TB. Differential efficacy of lipophilic and cytosolic antioxidants on generation of reactive oxygen species by amyloid-beta. J Alzheimers Dis 3: 525-529, 2001. (Pubitemid 34003204)
57. Di Domenico F, Sultana R, Tiu GF, Scheff NN, Perluigi M, Cini C, and Butterfield DA. Protein levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: an investigation on the role of cellular stress response in the progression of Alzheimer disease. Brain Res 1333: 72-81, 2010.
58. Ding Q, Markesbery WR, Cecarini V, and Keller JN. Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer's disease. Neurochem Res 31: 705-710, 2006. (Pubitemid 43886420)
59. Doorn JA, Maser E, Blum A, Claffey DJ, and Petersen DR. Human carbonyl reductase catalyzes reduction of 4-oxonon-2-enal. Biochemistry 43: 13106-13114, 2004. (Pubitemid 39366059)
60. Doorn JA and Petersen DR. Covalent adduction of nucleophilic amino acids by 4-hydroxynonenal and 4-oxononenal. Chem Biol Interact 143-144: 93-100, 2003. (Pubitemid 36246435)
61. Du AT, Schuff N, Amend D, Laakso MP, Hsu YY, Jagust WJ, Yaffe K, Kramer JH, Reed B, Norman D, Chui HC, and Weiner MW. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry 71: 441-447, 2001. (Pubitemid 32906865)
62. Duan Z, Lamendola DE, Yusuf RZ, Penson RT, Preffer FI, and Seiden MV. Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res 22: 1933-1941, 2002. (Pubitemid 34857007)
63. Dumont M, Wille E, Stack C, Calingasan NY, Beal MF, and Lin MT. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J 23: 2459-2466, 2009.
64. Duyckaerts C, Delatour B, and Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118: 5-36, 2009.
65. Economou A, Papageorgiou SG, Karageorgiou C, and Vassilopoulos D. Nonepisodic memory deficits in amnestic MCI. Cogn Behav Neurol 20: 99-106, 2007. (Pubitemid 46905205)
66. Eismann T, Huber N, Shin T, Kuboki S, Galloway E, Wyder M, Edwards MJ, Greis KD, Shertzer HG, Fisher AB, and Lentsch AB. Peroxiredoxin-6 protects against mitochondrial dysfunction and liver injury during ischemiareperfusion in mice. Am J Physiol Gastrointest Liver Physiol 296: G266-274, 2009.
67. Eliuk SM, Renfrow MB, Shonsey EM, Barnes S, and Kim H. active site modifications of the brain isoform of creatine kinase by 4-hydroxy-2-nonenal correlate with reduced enzyme activity: mapping of modified sites by Fourier transform-ion cyclotron resonance mass spectrometry. Chem Res Toxicol 20: 1260-1268, 2007. (Pubitemid 47548294)
68. Esterbauer H, Benedetti A, Lang J, Fulceri R, Fauler G, and Comporti M. Studies on the mechanism of formation of 4-hydroxynonenal during microsomal lipid peroxidation. Biochim Biophys Acta 876: 154-166, 1986. (Pubitemid 16011009)
69. Esterbauer H and Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 186: 407-421, 1990. (Pubitemid 20279982)
70. Esterbauer H, Schaur RJ, and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128, 1991. (Pubitemid 121003917)
71. Farooqui AA and Horrocks LA. Lipid peroxides in the free radical pathophysiology of brain diseases. Cell Mol Neurobiol 18: 599-608, 1998. (Pubitemid 29012939)
72. Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, Kowall NW, Brown RH Jr, and Beal MF. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 69: 2064-2074, 1997. (Pubitemid 27452754)
73. Ferrante RJ, Shinobu LA, Schulz JB, Matthews RT, Thomas CE, Kowall NW, Gurney ME, and Beal MF. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol 42: 326-334, 1997. (Pubitemid 27391116)
74. Ferrer I. Differential expression of phosphorylated translation initiation factor 2 alpha in Alzheimer's disease and Creutzfeldt-Jakob's disease. Neuropathol Appl Neurobiol 28: 441-451, 2002. (Pubitemid 35425597)
75. Filipovic MR, Stanic D, Raicevic S, Spasic M, and Niketic V. Consequences of MnSOD interactions with nitric oxide: nitric oxide dismutation and the generation of peroxynitrite and hydrogen peroxide. Free Radic Res 41: 62-72, 2007. (Pubitemid 44896875)
76. Fleuranceau-Morel P, Barrier L, Fauconneau B, Piriou A, and Huguet F. Origin of 4-hydroxynonenal incubationinduced inhibition of dopamine transporter and Na +K+ adenosine triphosphate in rat striatal synaptosomes. Neurosci Lett 277: 91-94, 1999.
77. Forrest GL and Gonzalez B. Carbonyl reductase. Chem Biol Interact 129: 21-40, 2000. (Pubitemid 32061052)
78. Francis PT, Palmer AM, Snape M, and Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66: 137-147, 1999. (Pubitemid 29103513)
79. Gadoni E, Olivero A, Miglietta A, Bocca C, and Gabriel L. Cytoskeletal modifications induced by 4-hydroxynonenal. Cytotechnology 11 Suppl 1: S62-64, 1993.
80. George AJ, Holsinger RM, McLean CA, Tan SS, Scott HS, Cardamone T, Cappai R, Masters CL, and Li QX. Decreased phosphatidylethanolamine binding protein expression correlates with Abeta accumulation in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Aging 27: 614-623, 2006. (Pubitemid 43290530)
81. Gomez A and Ferrer I. Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases. J Neurosci Res 87: 1002-1013, 2009.
82. Goshima Y, Nakamura F, Strittmatter P, and Strittmatter SM. Collapsin-Induced Growth Cone Collapse Mediated by an Intracellular Protein Related to Unc-33. Nature 376: 509-514, 1995.
83. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, and Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261: 6084-6089, 1986. (Pubitemid 17207447)
84. Guiotto A, Calderan A, Ruzza P, and Borin G. Carnosine and carnosine-related antioxidants: a review. Curr Med Chem 12: 2293-2315, 2005. (Pubitemid 41300782)
85. Gulesserian T, Engidawork E, Fountoulakis M, and Lubec G. Antioxidant proteins in fetal brain: superoxide dismutase-1 (SOD-1) protein is not overexpressed in fetal Down syndrome. J Neural Transm Suppl: 71-84, 2001. (Pubitemid 38085073)
86. Halliwell B and Gutteridge J. Free Radicals in Biology and Medicine. New York: Oxford University Press, 2007.
87. Hand CK and Rouleau GA. Familial amyotrophic lateral sclerosis. Muscle Nerve 25: 135-159, 2002. (Pubitemid 34117061)
88. Harjes P and Wanker EE. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 28: 425-433, 2003. (Pubitemid 36976745)
89. Hayes A and Batshaw ML. Down syndrome. Pediatr Clin North Am 40: 523-35, 1993. (Pubitemid 23159435)
90. Head E and Lott IT. Down syndrome and beta-amyloid deposition. Curr Opin Neurol 17: 95-100, 2004. (Pubitemid 38446448)
91. Heller SR and Macdonald IA. The measurement of cognitive function during acute hypoglycaemia: experimental limitations and their effect on the study of hypoglycaemia unawareness. Diabet Med 13: 607-615, 1996. (Pubitemid 26232500)
92. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM, et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 65: 2146-2156, 1995.
93. Hensley K, Venkova K, Christov A, Gunning W, and Park J. Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications. Mol Neurobiol 43: 180-191, 2011.
94. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490: 115-125, 2004. (Pubitemid 38482165)
95. Iannello RC, Crack PJ, de Haan JB, and Kola I. Oxidative stress and neural dysfunction in Down syndrome. J Neural Transm Suppl 57: 257-267, 1999.
96. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, and Brice A. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364: 1169-1171, 2004. (Pubitemid 39296605)
97. Inagaki N, Chihara K, Arimura N, Menager C, Kawano Y, Matsuo N, Nishimura T, Amano M, and Kaibuchi K. CRMP-2 induces axons in cultured hippocampal neurons. Nat Neurosci 4: 781-782, 2001. (Pubitemid 32702507)
98. Ishihara K, Amano K, Takaki E, Ebrahim AS, Shimohata A, Shibazaki N, Inoue I, Takaki M, Ueda Y, Sago H, Epstein CJ, and Yamakawa K. Increased lipid peroxidation in Down's syndrome mouse models. J Neurochem 110: 1965-1976, 2009.
99. Jouvenceau A, Dutar P, and Billard JM. Alteration of NMDA receptor-mediated synaptic responses in CA1 area of the aged rat hippocampus: contribution of GABAergic and cholinergic deficits. Hippocampus 8: 627-637, 1998. (Pubitemid 29010190)
100. Jovanovic SV, Clements D, and MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic Biol Med 25: 1044-1048, 1998. (Pubitemid 28558330)
101. Kehrer JP and Biswal SS. The molecular effects of acrolein. Toxicol Sci 57: 6-15, 2000.
102. Keller JN, Hanni KB, and Markesbery WR. Impaired proteasome function in Alzheimer's disease. J Neurochem 75: 436-439, 2000. (Pubitemid 30418211)
103. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, and Markesbery WR. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64: 1152-1156, 2005.
104. Kida K, Nishio T, Nagai K, Matsuda H, and Nakagawa H. Gluconeogenesis in the kidney in vivo in fed rats. Circadian change and substrate specificity. J Biochem (Tokyo) 91: 755-760, 1982. (Pubitemid 12116983)
105. Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, and Greensmith L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 10: 402-405, 2004. (Pubitemid 38508519)
106. Korenberg JR, Bradley C, and Disteche CM. Down syndrome: molecular mapping of the congenital heart disease and duodenal stenosis. Am J Hum Genet 50: 294-302, 1992.
107. Korolainen MA, Goldsteins G, Nyman TA, Alafuzoff I, Koistinaho J, and Pirttila T. Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain. Neurobiol Aging 27: 42-53, 2006. (Pubitemid 41627949)
108. Kruger R, Muller T, and Riess O. Involvement of alphasynuclein in Parkinson's disease and other neurodegenerative disorders. J Neural Transm 107: 31-40, 2000. (Pubitemid 30077040)
109. LaFontaineMA,MattsonMP, and Butterfield DA. Oxidative stress in synaptosomal proteins from mutant presenilin-1 knock-in mice: implications for familial Alzheimer's disease. Neurochem Res 27: 417-421, 2002. (Pubitemid 34579349)
110. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, and Butterfield DA. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J Neurochem 78: 413-416, 2001. (Pubitemid 32664423)
111. Lee J, Kosaras B, Del Signore SJ, Cormier K, McKee A, Ratan RR, Kowall NW, and Ryu H. Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington's disease mice. Acta Neuropathol 121: 487-498, 2011.
112. Lemieux N, Malfoy B, and Forrest GL. Human carbonyl reductase (CBR) localized to band 21q22.1 by highresolution fluorescence in situ hybridization displays gene dosage effects in trisomy 21 cells. Genomics 15: 169-172, 1993. (Pubitemid 23079585)
113. Li T, Hawkes C, Qureshi HY, Kar S, and Paudel HK. Cyclin-dependent protein kinase 5 primes microtubuleassociated protein tau site-specifically for glycogen synthase kinase 3beta. Biochemistry 45: 3134-3145, 2006. (Pubitemid 43376332)
114. Li YF, Wang Y, Channon KM, Schultz HD, Zucker IH, and Patel KP. Manipulation of neuronal nitric oxide synthase within the paraventricular nucleus using adenovirus and antisense technology. Methods Mol Med 112: 59-79, 2005.
115. Liochev SI and Fridovich I. Copper-and zinc-containing superoxide dismutase can act as a superoxide reductase and a superoxide oxidase. J Biol Chem 275: 38482-38485, 2000. (Pubitemid 32009174)
116. Liu D, Wen J, Liu J, and Li L. The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J 13: 2318-2328, 1999.
117. Liu R, Althaus JS, Ellerbrock BR, Becker DA, and Gurney ME. Enhanced oxygen radical production in a transgenic mouse model of familial amyotrophic lateral sclerosis. Ann Neurol 44: 763-770, 1998. (Pubitemid 28516047)
118. Loidl-Stahlhofen A, Hannemann K, and Spiteller G. Generation of alpha-hydroxyaldehydic compounds in the course of lipid peroxidation. Biochim Biophys Acta 1213: 140-148, 1994.
119. LoPachin RM and Barber DS. Synaptic cysteine sulfhydryl groups as targets of electrophilic neurotoxicants. Toxicol Sci 94: 240-255, 2006. (Pubitemid 44817140)
120. Lovell MA, Ehmann WD, Mattson MP, and Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18: 457-461, 1997. (Pubitemid 27497140)
121. Lovell MA and Markesbery WR. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res 35: 7497-7504, 2007.
122. Lucke C, Gantz DL, Klimtchuk E, and Hamilton JA. Interactions between fatty acids and alpha-synuclein. J Lipid Res 47: 1714-1724, 2006.
123. Macmillan-Crow LA and Cruthirds DL. Invited review: manganese superoxide dismutase in disease. Free Radic Res 34: 325-336, 2001. (Pubitemid 32331659)
124. Mann DM. The pathological association between Down syndrome and Alzheimer disease. Mech Ageing Dev 43: 99-136, 1988.
125. Markesbery WR and Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19: 33-36, 1998. (Pubitemid 28167792)
126. Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, and Wekstein DR. Neuropathologic substrate of mild cognitive impairment. Arch Neurol 63: 38-46, 2006. (Pubitemid 43063860)
127. Martinez A, Portero-Otin M, Pamplona R, and Ferrer I. Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol 20: 281-297, 2010.
128. Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M, and Terry R. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett 174: 67-72, 1994. (Pubitemid 24205235)
129. Mattson MP. Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders. Exp Gerontol 44: 625-633, 2009.
130. Mattson MP and Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci 7: 278-294, 2006.
131. Meier-Ruge W, Bertoni-Freddari C, and Iwangoff P. Changes in brain glucose metabolism as a key to the pathogenesis of Alzheimer's disease. Gerontology 40: 246-252, 1994. (Pubitemid 24221035)
132. Moreira PI, Santos MS, Oliveira CR, Shenk JC, Nunomura A, Smith MA, Zhu X, and Perry G. Alzheimer disease and the role of free radicals in the pathogenesis of the disease. CNS Neurol Disord Drug Targets 7: 3-10, 2008. (Pubitemid 351516211)
133. Morrow JD, Awad JA, Kato T, Takahashi K, Badr KF, Roberts LJ 2nd, and Burk RF. Formation of novel noncyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. J Clin Invest 90: 2502-2507, 1992. (Pubitemid 23010071)
134. Musiek ES, Yin H, Milne GL, and Morrow JD. Recent advances in the biochemistry and clinical relevance of the isoprostane pathway. Lipids 40: 987-994, 2005.
135. Napolitano A, Manini P, and d'Ischia M. Oxidation chemistry of catecholamines and neuronal degeneration: an update. Curr Med Chem 18: 1832-1845, 2011.
136. Neely MD, Boutte A, Milatovic D, and Montine TJ. Mechanisms of 4-hydroxynonenal-induced neuronal microtubule dysfunction. Brain Res 1037: 90-98, 2005. (Pubitemid 40362384)
137. Neely MD, Sidell KR, Graham DG, and Montine TJ. The lipid peroxidation product 4-hydroxynonenal inhibits neurite outgrowth, disrupts neuronal microtubules, and modifies cellular tubulin. J Neurochem 72: 2323-2333, 1999. (Pubitemid 29242182)
138. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, and Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60: 759-767, 2001. (Pubitemid 32678256)
139. Odetti P, Angelini G, Dapino D, Zaccheo D, Garibaldi S, Dagna-Bricarelli F, Piombo G, Perry G, Smith M, Traverso N, and Tabaton M. Early glycoxidation damage in brains from Down's syndrome. Biochem Biophys Res Commun 243: 849-851, 1998. (Pubitemid 28414171)
140. Ojika K, Tsugu Y, Mitake S, Otsuka Y, and Katada E. NMDA receptor activation enhances the release of a cholinergic differentiation peptide (HCNP) from hippocampal neurons in vitro. Brain Res Dev Brain Res 106: 173-180, 1998. (Pubitemid 28168483)
141. Op den Velde W and Stam FC. Some cerebral proteins and enzyme systems in Alzheimer's presenile and senile dementia. J Am Geriatr Soc 24: 12-16, 1976.
142. Oppermann U. Carbonyl reductases: the complex relationships of mammalian carbonyl-and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol 47: 293-322, 2007.
143. Orrenius S, Burgess DH, Hampton MB, and Zhivotovsky B. Mitochondria as the focus of apoptosis research. Cell Death Differ 4: 427-428, 1997.
144. Owen JB, Sultana R, Aluise CD, Erickson MA, Price TO, Bu G, Banks WA, and Butterfield DA. Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Abeta accumulation in AD brain. Free Radic Biol Med 49: 1798-1803, 2010.
145. Pallardo FV, Degan P, d'Ischia M, Kelly FJ, Zatterale A, Calzone R, Castello G, Fernandez-Delgado R, Dunster C, Lloret A, Manini P, Pisanti MA, Vuttariello E, and Pagano G. Multiple evidence for an early age pro-oxidant state in Down syndrome patients. Biogerontology 7: 211-220, 2006.
146. Pedersen WA, Cashman NR, and Mattson MP. The lipid peroxidation product 4-hydroxynonenal impairs glutamate and glucose transport and choline acetyltransferase activity in NSC-19 motor neuron cells. Exp Neurol 155: 1-10, 1999. (Pubitemid 29072599)
147. Perluigi M, di Domenico F, Fiorini A, Cocciolo A, Giorgi A, Foppoli C, Butterfield DA, Giorlandino M, Giorlandino C, Schinina ME, and Coccia R.
148. Perluigi M, Fai Poon H, Hensley K, Pierce WM, Klein JB, Calabrese V, De Marco C, and Butterfield DA. Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice-a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med 38: 960-968, 2005. (Pubitemid 40321087)
149. Perluigi M, Poon HF, Maragos W, Pierce WM, Klein JB, Calabrese V, Cini C, De Marco C, and Butterfield DA. Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease. Mol Cell Proteomics 4: 1849-1861, 2005. (Pubitemid 41830180)
150. Perluigi M, Sultana R, Cenini G, Di Domenico F, Memo M, Pierce WM, Coccia R, and Butterfield DA. Redox proteomics identification of 4-hydroxynonenal- modified brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin Appl 3: 682-693, 2009.
151. Pestova TV and Hellen CU. The structure and function of initiation factors in eukaryotic protein synthesis. Cell Mol Life Sci 57: 651-674, 2000. (Pubitemid 30311435)
152. Petersen DR and Doorn JA. Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med 37: 937-945, 2004. (Pubitemid 39164576)
153. Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 15: 93-101, 2000. (Pubitemid 30340226)
154. Petronis A. Alzheimer's disease and down syndrome: from meiosis to dementia. Exp Neurol 158: 403-413, 1999. (Pubitemid 29382830)
155. Poli G, Biasi F, and Leonarduzzi G. 4-Hydroxynonenalprotein adducts: A reliable biomarker of lipid oxidation in liver diseases. Mol Aspects Med 29: 67-71, 2008.
156. Poli G and Schaur RJ. 4-Hydroxynonenal in the pathomechanisms of oxidative stress. IUBMB Life 50: 315-321, 2000. (Pubitemid 32289090)
157. Poon HF, Calabrese V, Scapagnini G, and Butterfield DA. Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. J Gerontol A Biol Sci Med Sci 59: 478-493, 2004. (Pubitemid 38649940)
158. Poon HF, Hensley K, Thongboonkerd V, Merchant ML, Lynn BC, Pierce WM, Klein JB, Calabrese V, and Butterfield DA. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice-a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med 39: 453-462, 2005. (Pubitemid 41021644)
159. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, and Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 59: 972-976, 2002. (Pubitemid 34640757)
160. Pratico D, Iuliano L, Amerio G, Tang LX, Rokach J, Sabatino G, and Violi F. Down's syndrome is associated with increased 8,12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann Neurol 48: 795-798, 2000.
161. Pratt DA, Tallman KA, and Porter NA. Free radical oxidation of polyunsaturated lipids: New mechanistic insights and the development of peroxyl radical clocks. Acc Chem Res 44: 458-467, 2011.
162. Price DL. New perspectives on Alzheimer's disease. Annu Rev Neurosci 9: 489-512, 1986. (Pubitemid 16055794)
163. Pryor WA and Porter NA. Suggested mechanisms for the production of 4-hydroxy-2-nonenal from the autoxidation of polyunsaturated fatty acids. Free Radic Biol Med 8: 541-543, 1990. (Pubitemid 20204418)
164. Qin J, Goswami R, Balabanov R, and Dawson G. Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J Neurosci Res 85: 977-984, 2007. (Pubitemid 46580339)
165. Rakhit R, Cunningham P, Furtos-Matei A, Dahan S, Qi XF, Crow JP, Cashman NR, Kondejewski LH, and Chakrabartty A. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J Biol Chem 277: 47551-47556, 2002. (Pubitemid 36159274)
166. Rapoport SI. In vivo PET imaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 249 Suppl 3: 46-55, 1999.
167. Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, Coccia R, Markesbery WR, and Butterfield DA. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis 30: 107-120, 2008.
168. Reed TT. Lipid peroxidation and neurodegenerative disease. Free Radic Biol Med 51: 1302-1319, 2011.
169. Reed TT, Pierce WM, Markesbery WR, and Butterfield DA. Proteomic identification of HNE-bound proteins in early Alzheimer disease: insights into the role of lipid peroxidation in the progression of AD. Brain Res 1274: 66-76, 2009.
170. Roberts LJ 2nd, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, Dettbarn WD, and Morrow JD. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 273: 13605-13612, 1998. (Pubitemid 28268404)
171. Roper RJ and Reeves RH. Understanding the basis for Down syndrome phenotypes. PLoS Genet 2: e50, 2006.
172. Rossor MN, Iversen LL, Johnson AJ, Mountjoy CQ, and Roth M. Cholinergic deficit in frontal cerebral cortex in Alzheimer's disease is age dependent. Lancet 2: 1422, 1981.
173. Rozzini L, Chilovi BV, Conti M, Bertoletti E, Delrio I, Trabucchi M, and Padovani A. Conversion of amnestic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration. Int J Geriatr Psychiatry 22: 1217-1222, 2007. (Pubitemid 350285426)
174. Rubinsztein DC, Leggo J, Coles R, Almqvist E, Biancalana V, Cassiman JJ, Chotai K, Connarty M, Crauford D, Curtis A, Curtis D, Davidson MJ, Differ AM, Dode C, Dodge A, Frontali M, Ranen NG, Stine OC, Sherr M, Abbott MH, Franz ML, Graham CA, Harper PS, Hedreen JC, Hayden MR, et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 59: 16-22, 1996. (Pubitemid 26189723)
175. Ruiperez V, Darios F, and Davletov B. Alpha-synuclein, lipids and Parkinson's disease. Prog Lipid Res 49: 420-428, 2010.
176. Sajdel-Sulkowska EM and Marotta CA. Alzheimer's disease brain: alterations in RNA levels and in a ribonucleaseinhibitor complex. Science 225: 947-949, 1984. (Pubitemid 14064179)
177. Salmon M, Dedessus Le Moutier J, Wenders F, Chiarizia S, Eliaers F, Remacle J, Royer V, Pascal T, and Toussaint O. Role of the PLA2-independent peroxiredoxin VI activity in the survival of immortalized fibroblasts exposed to cytotoxic oxidative stress. FEBS Lett 557: 26-32, 2004. (Pubitemid 38115864)
178. Schapira AH. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim Biophys Acta 1410: 159-170, 1999. (Pubitemid 29078602)
179. Scheff SW, DeKosky ST, and Price DA. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging 11: 29-37, 1990. (Pubitemid 20097857)
180. Scheff SW and Price DA. Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J Alzheimers Dis 9: 101-115, 2006. (Pubitemid 44253303)
181. Scheff SW, Price DA, Schmitt FA, DeKosky ST, and Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68: 1501-1508, 2007. (Pubitemid 46685921)
182. Schneider C, Porter NA, and Brash AR. Autoxidative transformation of chiral omega6 hydroxy linoleic and arachidonic acids to chiral 4-hydroxy-2E-nonenal. Chem Res Toxicol 17: 937-941, 2004. (Pubitemid 38955353)
183. Shaw PJ, Ince PG, Falkous G, and Mantle D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol 38: 691-695, 1995.
184. Shibata N, Nagai R, Uchida K, Horiuchi S, Yamada S, Hirano A, Kawaguchi M, Yamamoto T, Sasaki S, and Kobayashi M. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 917: 97-104, 2001. (Pubitemid 32972133)
185. Shichiri M, Yoshida Y, Ishida N, Hagihara Y, Iwahashi H, Tamai H, and Niki E. alpha-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome. Free Radic Biol Med 50: 1801-1811, 2011.
186. Shinder GA, Lacourse MC, Minotti S, and Durham HD. Mutant Cu/Zn-superoxide dismutase proteins have altered solubility and interact with heat shock/stress proteins in models of amyotrophic lateral sclerosis. J Biol Chem 276: 12791-12796, 2001.
187. Siegel SJ, Bieschke J, Powers ET, and Kelly JW. The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry 46: 1503-1510, 2007.
188. Singh AK, Gupta S, and Jiang Y. Oxidative stress and protein oxidation in the brain of water drinking and alcohol drinking rats administered the HIV envelope protein, gp120. J Neurochem 104: 1478-1493, 2008. (Pubitemid 351316762)
189. Siow RC, Ishii T, and Mann GE. Modulation of antioxidant gene expression by 4-hydroxynonenal: atheroprotective role of the Nrf2/ARE transcription pathway. Redox Rep 12: 11-15, 2007. (Pubitemid 46210347)
190. Smith RG, Henry YK, Mattson MP, and Appel SH. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 44: 696-699, 1998. (Pubitemid 28477861)
191. Sperandio S, Poksay KS, Schilling B, Crippen D, Gibson BW, and Bredesen DE. Identification of new modulators and protein alterations in non-apoptotic programmed cell death. J Cell Biochem 111: 1401-1412, 2010.
192. Stockl M, Fischer P, Wanker E, and Herrmann A. Alphasynuclein selectively binds to anionic phospholipids embedded in liquid-disordered domains. J Mol Biol 375: 1394-1404, 2008.
193. Subba Rao K. Mechanisms of disease: DNA repair defects and neurological disease. Nat Clin Pract Neurol 3: 162-172, 2007.
194. Subbarao KV, Richardson JS, and Ang LC. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 55: 342-345, 1990.
195. Subramaniam R, Roediger F, Jordan B, Mattson MP, Keller JN, Waeg G, and Butterfield DA. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J Neurochem 69: 1161-1169, 1997. (Pubitemid 27364837)
196. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Markesbery WR, Zhou XZ, Lu KP, and Butterfield DA. Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis. Neurobiol Aging 27: 918-925, 2006.
197. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Merchant M, Markesbery WR, and Butterfield DA. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging 27: 1564-1576, 2006. (Pubitemid 44344840)
198. Sultana R and Butterfield DA. Oxidatively modified GST and MRP1 in Alzheimer's disease brain: implications for accumulation of reactive lipid peroxidation products. Neurochem Res 29: 2215-2220, 2004. (Pubitemid 40036893)
199. Sultana R and Butterfield DA. Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis 19: 341-353, 2010.
200. Sultana R, Perluigi M, and Butterfield DA. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Signal 8: 2021-2037, 2006. (Pubitemid 46499264)
201. Thompson JE, Hopkins MT, Taylor C, and Wang TW. Regulation of senescence by eukaryotic translation initiation factor 5A: implications for plant growth and development. Trends Plant Sci 9: 174-179, 2004. (Pubitemid 38448756)
202. Uchida K and Stadtman ER. Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. A possible involvement of intra-and intermolecular cross-linking reaction. J Biol Chem 268: 6388-6393, 1993. (Pubitemid 23099334)
203. Valentine JS. Do oxidatively modified proteins cause ALS? Free Radic Biol Med 33: 1314-1320, 2002. (Pubitemid 35284916)
204. Vander Jagt DL, Hunsaker LA, Vander Jagt TJ, Gomez MS, Gonzales DM, Deck LM, and Royer RE. Inactivation of glutathione reductase by 4-hydroxynonenal and other endogenous aldehydes. Biochem Pharmacol 53: 1133-1140, 1997. (Pubitemid 27224259)
205. Vayssiere JL, Cordeau-Lossouarn L, Larcher JC, Basseville M, Gros F, and Croizat B. Participation of the mitochondrial genome in the differentiation of neuroblastoma cells. In Vitro Cell Dev Biol 28A: 763-772, 1992. (Pubitemid 23054050)
206. Vexler ZS, Wong A, Francisco C, Manabat C, Christen S, Tauber M, Ferriero DM, and Gregory G. Fructose-1,6-bisphosphate preserves intracellular glutathione and protects cortical neurons against oxidative stress. Brain Res 960: 90-98, 2003. (Pubitemid 36044566)
207. Watanabe M, Dykes-Hoberg M, Culotta VC, Price DL, Wong PC, and Rothstein JD. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis 8: 933-941, 2001. (Pubitemid 34017087)
208. West MJ, Kawas CH, Stewart WF, Rudow GL, and Troncoso JC. Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol Aging 25: 1205-1212, 2004. (Pubitemid 39094023)
209. Wilkins MR, Sanchez JC, Williams KL, and Hochstrasser DF. Current challenges and future applications for protein maps and post-translational vector maps in proteome projects. Electrophoresis 17: 830-838, 1996. (Pubitemid 26000777)
210. Williams TI, Lynn BC, Markesbery WR, and Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol Aging 27: 1094-1099, 2006. (Pubitemid 43850642)
211. Yang Y, Sharma R, Sharma A, Awasthi S, and Awasthi YC. Lipid peroxidation and cell cycle signaling: 4-hydroxynonenal, a key molecule in stress mediated signaling. Acta Biochim Pol 50: 319-336, 2003. (Pubitemid 37034689)
212. Yarian CS, Rebrin I, and Sohal RS. Aconitase and ATP synthase are targets of malondialdehyde modification and undergo an age-related decrease in activity in mouse heart mitochondria. Biochem Biophys Res Commun 330: 151-156, 2005. (Pubitemid 40394947)
213. Yehuda S, Rabinovitz S, Carasso RL, and Mostofsky DI. The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol Aging 23: 843-853, 2002. (Pubitemid 35217710)
214. Yoshida H, Watanabe A, and Ihara Y. Collapsin response mediator protein-2 is associated with neurofibrillary tangles in Alzheimer's disease. J Biol Chem 273: 9761-9768, 1998. (Pubitemid 28183069)
215. Zana M, Janka Z, and Kalman J. Oxidative stress: a bridge between Down's syndrome and Alzheimer's disease. Neurobiol Aging 28: 648-676, 2007. (Pubitemid 46349350)
216. Zarkovic K. 4-hydroxynonenal and neurodegenerative diseases. Mol Aspects Med 24: 293-303, 2003. (Pubitemid 36945029)
217. Zhu M, Qin ZJ, Hu D, Munishkina LA, and Fink AL. Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles. Biochemistry 45: 8135-8142, 2006. (Pubitemid 43993234)